Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00067093 | Safety and Efficacy Trial Evaluating the Use of SR34006 in the Treatment of Deep Vein Thrombosis (DVT) | PHASE3 | COMPLETED | 1,452 | — | — | May 1, 2003 | Sep 1, 2005 | Apr 6, 2011 | 24 | United States |
| Name | Type | Description |
|---|---|---|
| SanOrg34006 | DRUG | - |
| LMW heparin | DRUG | - |
| Unfractionated heparin | DRUG | - |
| Vitamin K antagonist (VKA) | DRUG | - |
Inclusion Criteria: * Confirmed acute symptomatic DVT * Written informed consent Exclusion Criteria: * Legal lower age limitations * Patients with symptomatic pulmonary embolism * Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current episode of DVT * Other...